Top entities: Quoin Pharmaceuticals, United States — Food and Drug Administration, Michael Myers, United States, European Union.

What category does this event fall under?

Regulatory — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

United States — Food and Drug Administration cleared IND application Quoin Pharmaceuticals · Quoin Pharmaceuticals announced IND clearance · Quoin Pharmaceuticals plans to initiate Phase 2 study

Is this event still developing?

This is an active story, last updated Jul 09, 2026. Coverage continues to evolve.

Regulatory regulatory approval

Quoin Pharma FDA IND Clearance for QRX003

Q: When did this event occur?

First reported Jul 09, 2026; last updated Jul 09, 2026.

Q: What is the market impact?

General. The FDA clearance is a positive regulatory milestone for Quoin Pharmaceuticals, potentially expanding its pipeline and addressing an unmet medical need.

Analysis based on 7 articles · First reported Jul 09, 2026 · Last updated Jul 09, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The FDA clearance is a positive regulatory milestone for Quoin Pharmaceuticals, potentially expanding its pipeline and addressing an unmet medical need. However, the stock declined over 8% in pre-market trading, possibly due to profit-taking or market skepticism about the small study size and long timeline to approval.

Pharmaceuticals Biotechnology

Event Summary

Quoin Pharmaceuticals Ltd. announced that the U.S. United States — Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of a Phase 2 clinical study. This is the first-ever formal clinical study for a potential PSS therapy, and the second IND cleared indication for QRX003, in addition to Netherton Syndrome. The Phase 2 study is expected to enroll 6-8 pediatric and adult patients in the U.S. and Europe, with QRX003 applied twice daily over 52 weeks. The FDA expressed no safety concerns regarding study design or dosing duration. Quoin also plans to complete enrollment in its Phase 3 study for Netherton Syndrome by end of 2026 and seek FDA approval in 2027. Quoin's stock fell over 8% in pre-market trading following the announcement.

Key Actions

100 United States — Food and Drug Administration cleared IND application Quoin Pharmaceuticals

90 Quoin Pharmaceuticals announced IND clearance

80 Quoin Pharmaceuticals plans to initiate Phase 2 study

70 Quoin Pharmaceuticals reported no adverse events

Entities Involved

stock

Quoin Pharmaceuticals

Quoin Pharmaceuticals received FDA IND clearance for QRX003 in Peeling Skin Syndrome, enabling a Phase 2 study. The company's stock fell over 8% in pre-market trading, reflecting mixed market sentiment.

Importance 100.0 Sentiment 10.0

govactor

United States — Food and Drug Administration

The FDA cleared the IND application for QRX003, expressing no safety concerns. This regulatory action allows Quoin to proceed with clinical development.

Importance 80.0 Sentiment 0.0

per

Michael Myers

As CEO of Quoin Pharmaceuticals, Dr. Michael Myers commented on the significance of the FDA clearance for patients with Peeling Skin Syndrome.

Importance 50.0 Sentiment 10.0

cnt

United States

The Phase 2 study will enroll patients in the United States, and the FDA is the regulatory authority clearing the IND.

Importance 30.0 Sentiment 0.0

alliance

European Union

The Phase 2 study will enroll patients in Europe, and QRX003 has Orphan Drug Designation in the EU for Netherton Syndrome.

Importance 20.0 Sentiment 0.0

cnt

Japan

QRX003 has Orphan Drug Designation in Japan for Netherton Syndrome, but Japan is not directly involved in this event.

Importance 10.0 Sentiment 0.0

Relationships

United States — Food and Drug Administration related ↔ United States

United States — Food and Drug Administration related ↔ European Union

United States — Food and Drug Administration related ↔ Japan

United States related ↔ European Union

United States ally ↔ Japan The United States views Japan as a cornerstone ally in the Indo-Pacific, maintaining a mutual defense treaty, conducting

European Union related ↔ Japan

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard